Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a light therapy save failing kidney transplants?

NCT ID NCT04870437

Disease control Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a treatment called extracorporeal phototherapy (ECP) for people whose kidney transplants are failing due to chronic antibody-mediated rejection. ECP involves taking a patient's blood cells, treating them with a light-activated drug and UVA light, then returning them to the body to calm the immune system. The trial will enroll 30 adults to see if ECP can reduce harmful immune cells and help preserve the transplanted kidney.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extracorporeal phototherapy (ECP)
What this could lead to
If it works, this could offer a new treatment option to help prevent kidney transplant loss due to chronic rejection.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply broadly. The treatment's effectiveness is uncertain, and it involves a complex blood-processing procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ECP treatment decision based on transplant team habits (care management) * Age ≥ 18 years * Affiliation to a French social security scheme * Kidney transplant at least 6 months prior to inclusion * cABMR proven by a renal graft biopsy less than 3 months and meeting the following histological criteria: * allograft glomerulopathy (cg\>0, and maximum score cg2) or intimal fibrosis * C4d positive or ptc+g greater than or equal to 2 * Presence of Donor Specific Antibody (DSA) * Interstitial Fibrosis and Tubular Atrophy (IFTA) less than or equal to 2 * Glomerular filtration rate \> 30 mL/min/1.73 m2 * Signed informed consent to participate in the study Exclusion Criteria: * Active infection or infection with hepatitis B, C or HIV virus * Pregnant, breastfeeding or parturient woman * Person deprived of liberty by judicial or administrative decision * Person receiving psychiatric care under duress * Person subject to legal protection * Person out of state to express consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic antibody-mediated rejection in kidney transplant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Clermont Ferrand

    RECRUITING

    Clermont-Ferrand, France

  • CHU de STRASBOURG

    RECRUITING

    Strasbourg, France

  • Chu Besancon

    RECRUITING

    Besançon, France

  • Chu Saint Etienne

    RECRUITING

    Saint-Etienne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.